natgillin/translations-raw huggingface dataset:
A bifunctional molecule comprising a polypeptide binding partner specific for a given pMHC epitope, and an immune effector polypeptide, the N-terminus of the pMHC binding partner being linked to the C-terminus of the immune effector polypeptide, PROVIDED THAT the said polypeptide binding partner is not a T-cell receptor comprising the alpha chain SEQ ID No: 7 and the beta chain SEQ ID No: 9, and wherein the immune effector polypeptide is a cytokine. 
Bifunkcionalna molekula koja sadrži polipeptidni vezivajući partner specifičan za navedeni pMHC epitop, i imuni efektorni polipeptid, pri čemu je N-terminus pMHC vezivajućeg partnera vezan za C-terminus imunog efektornog polipeptida, UZ UVJET DA navedeni polipeptidni vezivajući partner nije T-stanični receptor koji sadrži alfa lanac SEQ ID No: 7 i beta lanac SEQ ID No: 9, pri čemu pMHC vezivajući partner je heterodimerni aβ TCR polipeptidni par, ili jednolančani aβ TCR polipeptid, i N-terminus a ili β lanca heterodimernog TCR polipeptidnog para ili N-terminus scTCR polipeptida, je vezan sa C-terminalnom aminokiselinom imunog efektornog polipeptida i pri čemu imuni efektorni polipeptid je antitijelo koje se specifično veže za antigen predstavljen preko T-stanice.
Use of a population of gold (Au) nanoparticles to prepare a pharmaceutical composition for use in a method of perturbing, altering or destroying target human cells in vivo, selected in the group consisting of benign cells, pre-malignant cells and malignant cells, when said cells are exposed to ionizing radiations, wherein the mean largest size of a nanoparticle of the population is between about 80 and 105 nm, and wherein the gold nanoparticle is covered with a biocompatible coating. 
Uporaba populacije zlatnih (Au) nanočestica za pripravu farmaceutskog sastava za uporabu u metodi narušavanja, izmjene ili uništavanja ciljnih ljudskih stanica in vivo, odabranih iz grupe koja se sastoji od benignih stanica, premalignih stanica i malignih stanica, pri čemu su navedene stanice izložene ionizirajućim zračenjima, gdje je prosječna najveća veličina nanočestice iz populacije između oko 80 i 105 nm, pri čemu je zlatna nanočestica prekrivena biokompatibilnom oblogom.
Pharmaceutical composition comprising a population of gold nanoparticles for use in a method of perturbing, altering or destroying target human cells in vivo, selected in the group consisting of benign cells, pre-malignant cells and malignant cells, when said cells are exposed to ionizing radiations, wherein the mean largest size of a nanoparticle of the population is between about 80 and 105 nm, and wherein the gold nanoparticle is covered with a biocompatible coating. 
Farmaceutski sastav obuhvaća populaciju zlatnih nanočestica za uporabu u metodi narušavanja, izmjene ili uništavanja ciljnih ljudskih stanica in vivo, odabranih iz grupe koja se sastoji od benignih stanica, premalignih stanica i malignih stanica, pri čemu su navedene stanice izložene ionizirajućim zračenjima, gdje je prosječna najveća veličina nanočestice iz populacije između oko 80 i 105 nm, pri čemu je zlatna nanočestica prekrivena biokompatibilnom oblogom.
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein the biocompatible coating is a non-biodegradable coating selected from the group consisting of silica, alumina, sugar, phosphate, silane, thiol, switterionic compound, lipid, saturated carbon polymer and an inorganic polymer; or a biodegradable coating selected from the group consisting of biological polymer, phospholipid, saccharide, oligosaccharide and polysaccharide. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu je biokompatibilna obloga ne-biorazgradiva obloga odabrana iz grupe koja se sastoji od silicija, aluminija, šećera, fosfata, silana, tiola, cviterionske tvari, lipida, zasićenog polimera ugljika i anorganskog polimera; ili biorazgradiva obloga odabrana iz grupe koja se sastoji od biološkog polimera, fosfolipida, saharida, oligosaharida i polisaharida.
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein the composition comprises between about 10-6 nmole and 10-3 nmole of gold per target cell. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu sastav obuhvaća između otprilike 10-6 nmola i 10-3 nmola zlata po ciljnoj stanici.
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein the nanoparticle comprises a surface component enabling specific targeting of biological tissues or cells. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu nanočestica obuhvaća površinsku komponentu koja omogućuje specifično ciljanje bioloških tkiva ili stanica.
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein the nanoparticle is essentially spherical or ovoid in shape. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu je nanočestica u osnovi sferičnog ili ovalnog oblika.
Use or pharmaceutical composition for use according to claim 7, wherein the ionizing radiations are of about 50 KeV to about 12 000 KeV. 
Uporaba farmaceutskog sastava za uporabu u skladu s patentnim zahtjevom 7, pri čemu su ionizirajuća zračenja oko 50 KeV do oko 12000 KeV.
Use or pharmaceutical composition for use according to claim 7, wherein the X-Rays radiations are of about 50 KeV to 6000 KeV. 
Uporaba farmaceutskog sastava za uporabu u skladu s patentnim zahtjevom 7, pri čemu su zračenja X-zraka oko 50 KeV do 6000 KeV.
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein said human malignant cells are cells from a solid tumor. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu su navedene maligne stanice stanice iz solidnog tumora.
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein the pharmaceutical composition further comprises an additional therapeutic compound intended to treat cancer, said additional therapeutic compound being distinct from the population of gold nanoparticles. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu farmaceutski sastav nadalje obuhvaća dodatnu terapijsku tvar namijenjenu za liječenje raka, navedena terapijska tvar je različita od populacije zlatnih nanočestica.
A method for inducing in vitro, ex vivo or in vivo the perturbation, lysis or destruction of target human cells selected from the group consisting of benign cells, pre-malignant cells and malignant cells, comprising i) contacting said target cells with a population of metallic nanoparticles during a period of time sufficient to allow the nanoparticles to interact with said cells, each nanoparticle of the population being made of a metal having an atomic number (Z) of at least 25, each metallic nanoparticle of the population being covered with a biocompatible coating, and the mean largest size of the nanoparticles of the population being between 80 and 105 nm, and, ii) exposing the cells to ionizing electromagnetic radiation, said exposure inducing or causing the perturbation, lysis or destruction of said cells. 
Uporaba populacije zlatnih (Au) nanočestica za pripravu farmaceutskog sastava za uporabu u metodi narušavanja, izmjene ili uništavanja ciljnih ljudskih stanica in vivo, odabranih iz grupe koja se sastoji od benignih stanica, premalignih stanica i malignih stanica, pri čemu su navedene stanice izložene ionizirajućim zračenjima, gdje je prosječna najveća veličina nanočestice iz populacije između oko 80 i 105 nm, pri čemu je zlatna nanočestica prekrivena biokompatibilnom oblogom.
The method according to claim 1, wherein said metallic nanoparticles comprises a surface component enabling specific targeting of biological tissues or cells. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu nanočestica obuhvaća površinsku komponentu koja omogućuje specifično ciljanje bioloških tkiva ili stanica.
Bow of a vessel according to the above claim 5, characterized in that both said leg (10a) of said acutely angled plate (1") disposed at the side wherein flow enters the duct and said leg (10b) of said acutely angled plate (1") disposed at the side wherein flow exits the duct are planar plates or plates of small convexity. 
Pramac plovila sukladno gornjem zahtjevu 5, naznačen time što obje noge (10a) izrazito nagnute ploče (1") smještene sa strane pri čemu protok ulazi u kanal i navedenu nogu (10b) izrazito nagnute ploče (1") smještene sa strane gdje protok izlazi iz kanala nalaze se ravne ploče ili ploče male konveksnosti.
Bow of a vessel according to any of the above claims 5-7, characterized in that the tops (10") and (20", 30") of said acutely angled plate (1") and (2", 3") respectively take the form of a linear portion of short length and/or of a rounded angle with a specified curved configuration. 
Pramac plovila sukladno bilo kojem od gornjih zahtjeva 5-7, naznačen time što vrhovi(10") i (20", 30") izrazito nagnute ploče (1") i (2", 3") odnosno uzimaju oblik linearnog dijela kratke duljine i/ili zaobljenog kuta sa specificiranom zakrivljenom konfiguracijom.
Bow of the vessel according to the above claims 1-16, characterized in that the lift coefficient CL1 of section (a) of the horizontal wall portion (1) is under all circumstances equal or higher than the lift coefficient CL2,3 of section (b) of the lateral wall portions (2, 3), the duct being designed so that the ratio CL1/CL2,3 for a specified hull designed for a specific nominal speed of the vessel is increasingly higher as the nominal speed of the vessel is increased, such increased nominal speed consequently resulting in the increase of wave making. 
Pramac plovila sukladno gornjim zahtjevima 1-16, naznačen time što koeficijent podizanja CL1 dijela (a) horizontalnog dijela zida (1) je u svim okolnostima jednak ili viši koeficijentu CL2,3 dijela (b) lateralnih dijelova zida (2, 3), kanal je projektiran na način da omjer CL1/CL2,3 za specificirani trup projektiran za specifičnu nominalnu brzinu plovila je značajno viši kako se nominalna brzina plovila povećava, takva povećana nominalna brzina posljedično rezultira povećanjem nastanka valova.
Bow of a vessel according to the above claim 1, characterized in that the lateral wall portions (2, 3) follow the geometry of the bow in the keel-to-deck direction, maintaining a constant distance from the sides of the bow and in that the wall portions (2, 3) are being oriented in a position parallel or at a certain inclination with respect to the waterline of the fully loaded condition of the vessel, whilst the imaginary line passing through the successive positions of the leading edges (2a, 3a) of the lateral wall portions (2, 3) is oriented in a direction parallel to the bow line. 
Pramac plovila sukladno gornjem zahtjevu 1, naznačen time što lateralni dijelovi zida (2, 3) prate geometriju pramca u smjeru kobilica-paluba, održavajući stalnu udaljenost od strana pramca i time što su dijelovi zida (2, 3) orijentirani u položaju paralelnom ili pri određenom nagibu u odnosu na liniju vode broda pod punim teretom, dok zamišljena linija prolazi kroz uzastopne položaje vodećih bridova (2a, 3a) lateralnih dijelova zida (2, 3) je orijentiran u smjeru paralenom s linijom pramca.
at least a vinyl copolymer block containing epoxy groups so that there is from 0.7% to 19% by weight of oxirane oxygen calculated on the total of block copolymer; and 
barem vinilni kopolimerni blok koji sadrži epoksi skupine tako da ima od 0,7% do 19% težine oksiran kisika računato prema ukupnom bloku kopolimera; i
from 0.03 phr by weight to 10 phr by weight, calculated on the base of component (a), of at least a halogenated flame retardant. 
barem halogenirani teško zapaljivi materijal (retardant) od 0,03 phr težine do 10 phr težine, računato na bazi komponente (a).
The self-extinguishing polymeric composition according to claim 2 which further comprises from 0.1 phr to 1 phr by weight, calculated on the base of component (a), of a synergic agent. 
Samogaseći polimerni pripravak prema zahtjevu 2 koji dalje obuhvaća sinergijsko sredstvo od 0,1 phr do 1 phr težine, računato na bazi komponente (a).
The self-extinguishing polymeric composition according to claim 4 which further comprises from 1 phr by weight to 10 phr by weight, calculated on the base of component (a), of an expanding agent. 
Samogaseći polimerni pripravak prema zahtjevu 4 koji dalje sadrži ekspandirajuće sredstvo od 1 phr težine do 10 phr težine, računato na bazi komponente (a).
The self-extinguishing polymeric composition according to anyone of claims from 1 to 5 which further comprises from 0 phr by weight to 25 phr by weight, calculated on the base of component (a), of an athermanous additive. 
Samogaseći polimerni pripravak prema bilo kojem od zahtjeva 1 do 5 koji dalje sadrži atermani aditiv (nepropustan za toplinsko zračenje) od 0 phr težine do 25 phr težine, računato na bazi komponente (a).
The self-extinguishing polymeric composition according to claim 7 which further comprises from 1 phr by weight to 20 phr by weight, calculated on the base of component (a), of an athermanous additive. 
Samogaseći polimerni pripravak prema zahtjevu 7 koji dalje sadrži atermani aditiv od 1 phr težine do 20 phr težine, računato na bazi komponente (a).
from 0.03 phr by weight to 10 phr by weight, calculated on the base of component (a), of at least one halogenated flame retardant, 
barem halogenirani teško zapaljivi materijal (retardant) od 0,03 phr težine do 10 phr težine, računato na bazi komponente (a).
The self-extinguishing polymeric composition according to claim 1 which comprises from 0 phr to 4 phr by weight, calculated on the base of component (a), of a synergic agent. 
Samogaseći polimerni pripravak prema zahtjevu 1 koji dalje obuhvaća sinergijsko sredstvo od 1 phr do 4 phr težine, računato na bazi komponente (a).
The self-extinguishing polymeric composition according to claim 2 which comprises from 0.1 phr to 1 phr by weight, calculated on the base of component (a), of said synergic agent. 
Samogaseći polimerni pripravak prema zahtjevu 2 koji dalje obuhvaća sinergijsko sredstvo od 0,1 phr do 1 phr težine, računato na bazi komponente (a).
The self-extinguishing polymeric composition according to claim 4 which comprises from 1 phr by weight to 10 phr by weight, calculated on the base of component (a), of said expanding agent. 
Samogaseći polimerni pripravak prema zahtjevu 4 koji dalje sadrži ekspandirajuće sredstvo od 1 phr težine do 10 phr težine, računato na bazi komponente (a).
The self-extinguishing polymeric composition according to claim 1 which comprises from 0 phr by weight to 25 phr by weight, calculated on the base of component (a), of an athermanous additive. 
Samogaseći polimerni pripravak prema bilo kojem od zahtjeva 1 do 5 koji dalje sadrži atermani aditiv (nepropustan za toplinsko zračenje) od 0 phr težine do 25 phr težine, računato na bazi komponente (a).
The self-extinguishing polymeric composition according to claim 7 which comprises from 1 phr by weight to 20 phr by weight, calculated on the base of component (a), of said athermanous additive. 
Samogaseći polimerni pripravak prema zahtjevu 7 koji dalje sadrži atermani aditiv od 1 phr težine do 20 phr težine, računato na bazi komponente (a).
A process for the preparation of a compound of formula Va or Vb wherein Pg is an amino protecting group, and Z is hydrogen, hydroxyethyl or a group convertible to hydroxyethyl, the process comprising the steps of: 
Postupak za proizvodnju spoja sljedeće formule Va ili Vb: [image] naznačen time, da Pg je amino-zaštitna skupina, a Z je vodik, hidroksietil ili skupina koja se može pretvarati u hidroksietil, pri čemu postupak obuhvaća sljedeće korake:
reducing the nitro group in the compound of formula IIIa' or IIIb' to an amino group to obtain a compound of formula IVa' or IVb', respectively, and 
redukcija nitro-skupine iz spoja formule IIIa' odnosno IIIb' u amino-skupinu, kako bi se dobio spoj sljedeće formule IVa' odnosno IVb':
nitrosation of the compound of formula IVa' or IVb' to obtain the compound of formula Va or Vb, respectively. 
[image] i nitrozacija spoja formule IVa' odnosno IVb', kako bi se dobio spoj formule Va odnosno Vb.
(0-2') reacting the compound of formula la with a compound of the formula to obtain a compound of formula IIa, and 
[image] (0-2') reakcija spoja formule Ia sa spojem sljedeće formule: [image] kako bi se dobio spoj sljedeće formule IIa:
(0-3') introducing an amino protecting group Pg to obtain the compound of formula II' . 
[image] i (0-3') uvođenje amino-zaštitne skupine Pg, kako bi se dobio spoj formule II'.
The process according to claim 1 or 2, wherein the steps (i) to (iii), optionally also the preparation of the compound of formula II', are carried out in one pot. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da se koraci od (i) do (iii), prema potrebi također i proizvodnja spoja formule II', provode u jednolončanom postupku.
The process according to any one of the preceding claims, wherein Z is hydrogen or a group convertible to hydroxyethyl, and after the preparation of the compound of formula Va, a hydroxyethyl group is introduced to obtain a compound of formula Va' 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da Z je vodik ili skupina koja se može pretvarati u hidroksietil, a nakon proizvodnje spoja formule Va, uvodi se hidroksietil-skupina, kako bi se dobio spoj sljedeće formule Va': [image]
optionally forming a salt of the compound of formula VIII, 
prema potrebi tvorba soli od spoja formule VIII.
Process for the preparation of a pharmaceutical composition comprising a compound of formula VIII or a salt thereof comprising the steps of: 
Postupak za proizvodnju farmaceutskog sastava koji sadrži spoj sljedeće formule VIII ili njegovu sol:
preparing a compound of formula VIII or a salt thereof according to claim 7, and 
proizvodnja spoja formule VIII ili njegove soli prema zahtjevu 7, i
mixing the compound of formula VIII or a salt thereof with a pharmaceutically acceptable carrier and/or excipient. 
miješanje spoja formule VIII ili njegove soli, s farmaceutski prihvatljivim nosačem i/ili s pomoćnim sredstvom.
A compound according to claim 1 wherein X together with Y form -CH=CH- or -CH2-O- group, preferably X together with Y form -CH=CH- group. 
Spoj prema zahtjevu 1, naznačen time, što X zajedno s Y formira -CH=CH- ili -CH2-O- grupu, poželjno X zajedno s Y formira -CH=CH- grupu.
The process according to claim 1 or 2, characterized in that a portion of the useful output energy is fed back to cool the mobile particles as necessary to maintain steady state. 
Proces u skladu sa patentnim zahtjevom 1 ili 2, naznačen time da je dio korisne izlazne energije vraćen nazad da ohladi pokretne čestice da se ako je neophodno održi stabilno stanje.
The isolated human antibody or antigen-binding fragment of any one of claims 1 to 7 or the pharmaceutical composition of claim 8 for use in a method of treating a patient, wherein the patient exhibits one or more symptoms or indicia of a disease or disorder caused by PAR-2 activity wherein the disease or disorder caused by PAR-2 activity is a disease or disorder selected from the group consisting of pain, pruritus, asthma, rheumatoid arthritis, fibrosis, atopic dermatitis, inflammatory bowel disease, ulcerative colitis, pancreatitis, ulcer, Crohn's disease, cancer, and Netherton's disease. 
Izolirano ljudsko antitijelo ili antigen vezujući fragment prema bilo kojem zahtjevu od 1 do 7 ili farmaceutski pripravak prema zahtjevu 8 za primjenu u načinu liječenja bolesnika, naznačen time, što spomenuti bolesnik ima jedan ili više simptoma ili indikatora bolesti ili poremećaja izazvanog aktivnošću PAR-2, pri čemu je bolest ili poremećaj izazvan aktivnošću PAR-2 bolest ili poremećaj odabran iz grupe koja se sastoji od boli, pruritusa, astme, reumatoidnog artritisa, fibroze, atopičnog dermatitisa, upalne bolesti crijeva, ulcerativnog kolitisa, pankreatitisa, čira, Chronove bolesti, raka i Nethertonove bolesti.
The isolated antibody, antigen-binding fragment or composition of claim 9, for use according to claim 9, where the method further comprises administering to the patient at least one additional therapeutically active component selected from the group consisting of an IL-1 inhibitor, an IL-18 inhibitor, an IL-4 inhibitor, an IL-4 receptor inhibitor, an IL-6 inhibitor, an IL-6 receptor inhibitor, a nerve growth factor (NGF) inhibitor, a tumor necrosis factor (TNF) inhibitor, a TNF receptor inhibitor, a uric acid synthesis inhibitor and a corticosteroid. 
Izolirano antitijelo, antigen vezujući fragment ili pripravak prema zahtjevu 9, za primjenu prema zahtjevu 9, pri čemu se način dodatno sastoji od davanja bolesniku najmanje jednog dodatnog terapijski aktivnog sastojka odabranog iz grupe koja se sastoji od inhibitora IL-1, inhibitora IL-18, inhibitora IL-4, inhibitora receptora IL-4, inhibitora IL-6, inhibitora receptora IL-6, inhibitora nervnog faktora rasta (NGF), inhibitora faktora nekroze tumora (TNF) i inhibitora receptora TNF-a, inhibitora sinteze mokraćne kiseline i kortikosteroida.
Use of the isolated antibody or antigen-binding fragment of any one of claims 1 to 7, or the pharmaceutical composition of claim 8, in the manufacture of a medicament for use in treating a patient who exhibits one or more symptoms or indicia of a disease or disorder caused by PAR-2 activity, wherein the disease or disorder caused by PAR-2 activity is a disease or disorder selected from the group consisting of pain, pruritus, asthma, rheumatoid arthritis, fibrosis, atopic dermatitis, inflammatory bowel disease, ulcerative colitis, pancreatitis, ulcer, Crohn's disease, cancer, and Netherton's disease. 
Primjena izoliranog antitijela ili antigen vezujućeg fragmenta prema bilo kojem zahtjevu od 1 do 7 ili farmaceutskog pripravka prema zahtjevu 8, u proizvodnji lijeka za primjenu u liječenju bolesnika koji ima jedan ili više simptoma ili indikatora bolesti ili poremećaja izazvanog aktivnošću PAR-2, pri čemu je bolest ili poremećaj izazvan aktivnošću PAR-2 bolest ili poremećaj odabran iz grupe koja se sastoji od boli, pruritusa, astme, reumatoidnog artritisa, fibroze, atopičnog dermatitisa, upalne bolesti crijeva, ulcerativnog kolitisa, pankreatitisa, čira, Chronove bolesti, raka i Nethertonove bolesti.
A pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable homopolymer or copolymer of N-vinylpyrrolidone and a solubilizing composition, the active ingredient being present as a solid dispersion and the solubilizing composition comprising (i) at least one tocopheryl compound that corresponds to formula (I) wherein 
Farmaceutska doza koja sadrži smjesu taline od barem jednog aktivnog sastojka, barem jednog farmaceutski prihvatljivog homopolimera ili kopolimera N-vinilpirolidona i otapajuća smjesa, pri čemu je aktivni sastojak prisutan kao čvrsta disperzija, a otapajuća smjesa sadrži (i) barem jedan tokoferol sastojak koji odgovara formuli (I) [image]